{
    "clinical_study": {
        "@rank": "107479", 
        "arm_group": [
            {
                "arm_group_label": "Z-360", 
                "arm_group_type": "Experimental", 
                "description": "1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1)Single dose study, 2)Multiple doses study"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics\n      (including food effect) of single and multiple doses of Z-360 in healthy Japanese subjects."
        }, 
        "brief_title": "A Healthy Subject Study With Z-360 and Placebo", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "This is a single centre, randomized, double-blind, placebo-controlled, parallel-group, and\n      food effect study.This is three parts study. The purpose of the first part (Part 1) is the\n      evaluation of the safety, tolerability, and pharmacokinetics after single ascending doses of\n      Z-360.The second part (Part 2 ) is the evaluation of the pharmacokinetics of food effect of\n      Z-360.The third part (Part 3) is the evaluation of the safety, tolerability, and\n      pharmacokinetics after multiple ascending doses of Z-360."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male subjects between 20 to 49 years of age inclusive\n\n          2. Body mass index (BMI) within the range 17.6 to 26.4 kg/m2 inclusive\n\n          3. The subject is capable of giving written informed consent prior to admission into\n             this study\n\n        Exclusion Criteria:\n\n          1. History or presence of drug hypersensitivity, drug dependence, narcotic dependence or\n             alcohol dependence\n\n          2. History or presence disease of digestive, liver, kidney, blood, cardiovascular,\n             neuropsychiatric which may affect participation or results of this study\n\n          3. Positive test for Hepatitis B surface antigen, Hepatitis C antibody, HIV antigen\n             antibody or Serological test for syphilis\n\n          4. Use of any medication within 1 week prior to dosing\n\n          5. Received any investigational drugs with new active ingredients within 16 weeks prior\n             to dosing the study or received any investigational drugs in other clinical studies\n             within 12 weeks\n\n          6. Whole blood collection exceeding 200 mL within 4 weeks, apheresis within 2 weeks, or\n             blood withdrawal exceeding 400 mL within 12 weeks (blood donation, etc)  prior to\n             dosing\n\n          7. Others, patients who are unfit for the study as determined by the attending physician"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776463", 
            "org_study_id": "01A10101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Z-360", 
                "intervention_name": "Z-360", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Z-360", 
            "Japanese", 
            "pK"
        ], 
        "lastchanged_date": "September 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sumida-ku", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "130-0004"
                }, 
                "name": "Sumida"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Centre, Randomized, Double-blind, Ascending Dose, Placebo-controlled, and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Z-360 and Placebo in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Sumida", 
            "last_name": "Eri Sato, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "General safety and tolerability endpoints: (Adverse events, Vital signs, 12-lead ECG and clinical laboratory safety tests)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776463"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "pK (AUC, Cmax, Tmax, T1/2, MRT, CL/F, V/F)", 
            "measure": "To evaluate the pharmacokinetics of single and multiple doses of Z-360 in healthy subjects", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks"
        }, 
        "source": "Zeria Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zeria Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}